Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
Deloitte
Chinese Patent Office
Citi
US Department of Justice
QuintilesIMS
Colorcon
Mallinckrodt
Harvard Business School

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,975,242

« Back to Dashboard

Which drugs does patent 8,975,242 protect, and when does it expire?


Patent 8,975,242 protects TYGACIL and is included in one NDA. There has been one Paragraph IV challenge on Tygacil.

This patent has twenty-six patent family members in twenty-three countries.

Summary for Patent: 8,975,242

Title:Tigecycline compositions and methods of preparation
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Inventor(s): Fawzi; Mahdi B. (Morristown, NJ), Zhu; Tianmin (Monroe, NY), Shah; Syed M. (East Hanover, NJ)
Assignee: Wyeth LLC (New York, NY)
Application Number:13/011,164
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Pf Prism CvTYGACILtigecyclinePOWDER;IV (INFUSION)021821-001Jun 15, 2005APRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,975,242

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,879,828Tigecycline compositions and methods of preparation► Subscribe
9,694,078Tigecycline compositions and methods of preparation► Subscribe
9,254,328Tigecycline compositions and methods of preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,975,242

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina053827► Subscribe
Australia2006223226► Subscribe
BrazilPI0608464► Subscribe
Canada2602089► Subscribe
China101132775► Subscribe
China102512429► Subscribe
Costa Rica9416► Subscribe
Cyprus1114504► Subscribe
Denmark1858488► Subscribe
European Patent Office1858488► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
McKesson
McKinsey
Healthtrust
Novartis
Colorcon
Johnson and Johnson
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot